The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia. - Toscan CE; McCalmont H; Ashoorzadeh A; Lin X; Fu Z; Doculara L; Kosasih HJ; Cadiz R; Zhou A; Williams S; Evans K; Khalili F; et al. (Blood cancer journal, 2024)